Covalent Peptide Attachment to Quantum Dots via Carbodiimide Chemistry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for covalent attachment of peptides and biological molecules to luminescent semiconductor nanocrystals or nanoparticles face challenges such as poor temporal stability, lack of pH stability, and difficulty in delivering quantum dot bioconjugates inside live cells for applications like fluorescence or FRET studies.
Innovation Solution
A method involving functionalizing quantum dots or nanoparticles with reactive groups and reacting peptides with these groups to achieve covalent bonding, allowing for customized fabrication of quantum dots with various functional properties and peptide combinations, including the use of DHLA-polyethylene glycol analogs for spacer control and peptide synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If electrostatic self-assembly with DHLA-capping is used to attach peptides to quantum dots, then the attachment process is simple, but the temporal stability and pH stability of the attachment is poor
Solution Approach 1:
The patent introduces an intermediary coupling chemistry system comprising a carboxylic acid component (from DHLA ligands on quantum dot surface), a coupling agent (EDC), and a crosslinking agent (BSA or NHS-BSA) that mediates the attachment between quantum dots and peptides/proteins. This intermediary system transforms the simple but unstable electrostatic assembly into a stable covalent attachment while maintaining ease of implementation.
Solution Approach 2:
The patent changes the chemical parameters of the attachment process by introducing EDC (a carbodiimide coupling agent) and BSA/NHS-BSA (crosslinking agents) to the system. These parameter changes enable covalent bond formation between the carboxylic acid groups on quantum dot surface and amino groups on peptides/proteins, dramatically improving temporal stability while maintaining pH stability across physiological ranges.
2Reliability
If DHLA-PEG ligands are used to expand pH solubility range, then solubility is improved, but the ability to form direct covalently linked nanocrystal-biomolecule conjugates in aqueous environments is lost
Solution Approach 1:
The patent applies preliminary action by first establishing the quantum dot surface chemistry with DHLA-PEG ligands to ensure pH stability and solubility, then introducing EDC and BSA crosslinking agents to enable subsequent covalent attachment of peptides/proteins in aqueous environments. This preliminary preparation of the surface chemistry allows both pH stability and covalent attachment capability to coexist.
3Manufacturing precision
If covalent attachment chemistry is used to achieve quantitative and qualitative control, then molecular display and physiochemical characteristics are optimized, but the complexity of controlling chemical parameters increases
Solution Approach 1:
The patent employs self-service principles where BSA (bovine serum albumin) acts as a self-assembling crosslinking agent that automatically forms covalent bonds between quantum dots and peptides/proteins through its multiple amino groups. This self-service mechanism simplifies the control of chemical parameters by allowing the system to self-regulate the attachment process, reducing the need for complex external control while achieving quantitative and qualitative optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables controlled, stable covalent attachment of peptides to quantum dots, providing enhanced stability, solubility, and the ability to create biofunctionalized quantum dots that can enter cells, facilitating applications in biomedical research and diagnostics.
Implementation Method 1
The coupling of the quantum dots to the peptide was performed using 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (EDC)
Implementation Method 2
N-hydroxysuccinimide-bovine serum albumin (NHS-BSA) crosslinking agents
Implementation Method 3
dihydrolipoic acid (DHLA) ligands
Data Source
AI summary
A method for covalent attachment of peptides to luminescent quantum dots or other inorganic nanoparticles. The first step in the method involves functionalizing at least a portion of a surface of the quantum dot or nanoparticle with one or more materials having at least one reactive functional group therein. Subsequently, a peptide having a reactive functional group is reacted with at least some of the quantum dot or nanoparticle reactive functional groups to covalently bond at least some of the peptide to the quantum dots or nanoparticles. Modifications of the basic method are disclosed which provide methods allowing customized fabrication of quantum dots having a variety of different functional properties and combinations of functional properties. Also disclosed are quantum dots and nanoparticles made by the methods of the present invention.